News & Updates

Anticoagulation during CKRT reduces dialysis, death in AKI patients

24 Sep 2023 by

Use of anticoagulants during continuous kidney replacement therapy (CKRT) helps lower dialysis dependence and prevent death at 90 days among critically ill patients with acute kidney injury (AKI) following admission to the intensive care unit (ICU), a study in Singapore has shown.

Anticoagulation during CKRT reduces dialysis, death in AKI patients

24 Sep 2023

Several factors must be considered when tapering adalimumab in noninfectious uveitis patients

24 Sep 2023

For patients who undergo adalimumab tapering after achieving remission, factors such as age, race, and duration of disease remission on adalimumab appear to impact the risk of relapse, according to a study.

Several factors must be considered when tapering adalimumab in noninfectious uveitis patients

24 Sep 2023

Tirzepatide a valuable therapeutic option for weight management

23 Sep 2023

Treatment with tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for type 2 diabetes, leads to substantial reductions in weight despite an increase in gastrointestinal symptoms, according to the results of a meta-analysis.

Tirzepatide a valuable therapeutic option for weight management

23 Sep 2023

$3-vessel CAD outcomes comparable with fractional flow reserve-guided PCI vs CABG$

3-vessel CAD outcomes comparable with fractional flow reserve-guided PCI vs CABG

23 Sep 2023

In the treatment of patients with 3-vessel coronary artery disease (CAD), fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) does not differ from coronary artery bypass grafting (CABG) in terms of the incidence of the composite of death, myocardial infarction (MI), or stroke, according to 3-year data from the FAME 3* trial.

3-vessel CAD outcomes comparable with fractional flow reserve-guided PCI vs CABG

23 Sep 2023

Benralizumab helps maintain severe asthma control with reduced ICS doses

22 Sep 2023 by

Treatment with benralizumab allows tapering of inhaled corticosteroid (ICS) doses for patients with severe eosinophilic asthma, without compromising disease control and increasing exacerbations, as shown in the results of the phase IV SHAMAL study.

Benralizumab helps maintain severe asthma control with reduced ICS doses

22 Sep 2023

Antidepressant use among HCC patients linked to lower risk of death

22 Sep 2023

For patients with hepatocellular carcinoma (HCC), the use of antidepressants after diagnosis may signal increased overall and cancer-specific survival, according to a study.

Antidepressant use among HCC patients linked to lower risk of death

22 Sep 2023

Pos Malaysia’s medication delivery service becoming popular

22 Sep 2023 by

Pos Malaysia’s Ubat Melalui Pos (UMP) service, launched in 2011, has been offering the delivery of prescription medication to patients located within the PosLaju area of coverage for a minimal fee.

Pos Malaysia’s medication delivery service becoming popular

22 Sep 2023

Benralizumab reduces asthma exacerbations in Asians

22 Sep 2023 by

Treatment with benralizumab significantly reduces the annual asthma exacerbation rate (AAER) among Asian patients with severe uncontrolled asthma compared with placebo, according to a subgroup analysis of the MIRACLE trial presented at ERS 2023.